CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 981 - 990 of 1137
Study Number Lead Group Study Title CIRB Study Status
10561 ETCTN Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab Adult CIRB - Early Phase Emphasis Available to Open
10559 ETCTN A Phase 2 Study of Erdafitinib in Patients with Recurrent or Progressive IDH-Wild Type Glioma with an FGFR-TACC Gene Fusion Adult CIRB - Early Phase Emphasis Available to Open
10558 ETCTN A Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors Adult CIRB - Early Phase Emphasis Available to Open
10556 ETCTN Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma Adult CIRB - Early Phase Emphasis Available to Open
10553 ETCTN A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer Adult CIRB - Early Phase Emphasis Available to Open
10551 ETCTN A Phase 1/1b Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in Patients with BRCA1/2-mutant Tumors Adult CIRB - Early Phase Emphasis Available to Open
10546 ETCTN Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer Adult CIRB - Early Phase Emphasis Available to Open
10538 ETCTN Venetoclax In Combination with ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 trial Adult CIRB - Early Phase Emphasis Available to Open
10528 ETCTN A Phase 1 Study of the Polymerase Theta (POLθ) Inhibitor Novobiocin in BRCA-mutant and Other DNA Damage Repair-Deficient Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
10527 ETCTN A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774 Adult CIRB - Early Phase Emphasis Available to Open
Displaying 981 - 990 of 1137